Serina Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Serina Therapeutics, Inc. (SER) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2019
Operating Activities
Net Income-11.145.27-2.68-8.58-12.38
Depreciation & Amortization0.190.090.061.251.01
Stock Based Compensation2.600.030.010.080.00
Change in Working Capital-3.320.08-0.01-0.99-0.34
Change in Accounts Receivable0.070.000.001.270.00
Change in Accounts Payable-1.660.390.00-0.370.00
Change in Other Working Capital-1.72-0.31-0.16-0.120.00
Other Operating Activities-5.81-7.940.541.001.92
Net Cash from Operating Activities-17.14-2.48-2.08-7.86-10.16
Investing Activities
Capital Expenditures-0.02-0.50-0.01-0.110.64
Acquisitions0.000.000.000.470.35
Purchases of Investments0.000.000.990.930.00
Sales/Maturities of Investments0.00-10.000.990.25-0.07
Other Investing Activities0.00-10.000.000.25-0.07
Net Cash from Investing Activities-0.02-0.500.980.67-0.36
Financing Activities
Debt Repayment-0.17-0.05-3.69-0.010.00
Common Stock Issued10.000.020.000.500.00
Other Financing Activities0.340.000.007.00-0.04
Net Cash from Financing Activities13.2110.071.317.256.27
Summary
Effect of Forex Changes on Cash0.000.000.000.000.00
Net Change in Cash-3.957.090.220.06-4.26
Cash at Beginning of Period7.620.700.310.586.71
Cash at End of Period3.670.400.530.632.45
Free Cash Flow-17.16-2.98-2.09-7.86-10.80
Supplemental Disclosures
Interest Paid0.000.030.020.010.01